Medical Doctor Program year 2020 Source: CMS Open Payments, 2026 publication

Jane Kauffman

Cardiovascular Disease West Hollywood, CA Medical Doctor

NPI 1528004470 CMS profile 377903

8733 Beverly Blvd, Suite 312, West Hollywood, CA 90048

Open in the dashboard

General payments

$23

1 record reported · program year 2020

Research payments

$0

Paid to them · None reported · program year 2020

Ownership & investment interest

$0

None reported

Through program year 2020, Jane Kauffman of West Hollywood, CA is reported in the CMS Open Payments database as having received $23 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 3rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2020 General $23 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jane Kauffman
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Jane Kauffman were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Jane Kauffman Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $23 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program year 2020
  1. Abbott Laboratories $23 1 payment

Every payment, record by record

What the payments were for General payments · program year 2020
  1. Food and Beverage $23 1 payment
Products named General payments · program year 2020
  1. Merlin Connectivity and Remote $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

13,135

Median for Cardiology: 2,533

Drug cost

$1,284,039

Median for Cardiology: $485,213

Branded share of claims

26.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,005 $608,546
Entresto Sacubitril/Valsartan Brand 391 $258,508
Xarelto Rivaroxaban Brand 269 $166,155
Repatha Sureclick Evolocumab Brand 91 $48,792
Benicar Olmesartan Medoxomil Brand 41 $21,744
Nebivolol Hcl Generic 522 $18,651
Edarbi Azilsartan Medoxomil Brand 67 $16,722
Captopril Generic 587 $14,520
Icosapent Ethyl Generic 85 $13,743
Multaq Dronedarone Hcl Brand 15 $13,034

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$424,085

Medicare's payments for the services billed

Medicare patients

807

Average age 80

Services billed

6,898

466 women, 341 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 72%
Diabetes 64%
Depression 53%
Heart failure 50%
Chronic kidney disease 42%
Atrial fibrillation 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record